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Abstract  28 
Objective: papillary thyroid microcarcinomas (microPTC) may be  “incidental” (Inc-29 
microPTC), occasionally found at histology after surgery for benign disease or “non-30 
incidental” (Non-Inc-microPTC), diagnosed on clinical grounds. It is unclear whether 31 
these different microPTC reflect the same disease. The aim of the study was to compare 32 
Inc-microPTC and Non-Inc-microPTC for clinical and histological features as well as for 33 
serum TSH, a known factor involved in PTC development.  34 
Design: We evaluated histology and serum TSH levels of consecutive patients submitted 35 
to thyroidectomy for goiter with compressive symptoms or for cytological diagnosis 36 
suspicious/indicative of PTC. 37 
Methods: 665 consecutive patients (259 with a single thyroid nodule, SN and 406 with a 38 
multinodular gland, MN) were included in the study. According to histology, patients were 39 
classified as: benign nodular goiter (Benign, n= 291); Inc-microPTC (n=92); Non-Inc-40 
microPTC (n= 67); PTC ≥ 1 cm (macroPTC, n = 215).  41 
Results: Inc-microPTC were significantly more frequent in MN than in SN (66/406, 16.2% 42 
vs 26/259,10.0%, p = 0.02). Patients with Inc-microPTC compared to Non-Inc-microPTC 43 
were older (mean age 53.3±13.2 years vs 44.9±14.8 years,
 
p=0.0002), had a smaller 44 
tumor size (median 4 mm vs 9 mm, 
 
p<0.0001), a higher frequency of multifocality (70/92, 45 
76.1% vs 35/67, 52.2% p=0.001) and lower levels of TSH (median 0.6 mU/L, IR 0.4-1.0 46 
mU/L vs value 1. mU/L, IR 0.6-1.4  mU/L vs p=0.0001).  47 
Conclusion: Incidental and Non-incidental papillary thyroid microcarcinomas appear to 48 
be two different entities  49 
 50 
51 




Thyroid cancer is the most common malignant tumor of the endocrine system and 54 
papillary thyroid cancer (PTC) accounts
 
for more than 80% of all thyroid malignancies. 55 
The frequency of PTC has been increasing in last years, mainly due to the diagnosis of 56 
small cancers (1-4). The increased incidence of thyroid cancer is likely related to an 57 
increased diagnosis due to the use of ultrasound and fine needle aspiration (5). Some 58 
authors have attributed this to the increasing identification of thyroid nodules during 59 
routine imaging for non thyroid-related conditions (e.g. radiological evaluations for carotid 60 
disease or magnetic resonance imaging for cervical disease) and the wide spread use of 61 
ultrasound guided fine needle aspiration cytology (6). As a result of this phenomenon, the 62 
frequency of papillary thyroid microcarcinomas (microPTC), defined by the World Health 63 
Organization as a PTC of 10 mm or less in the largest dimension (7), has increased 64 
considerably during the past two decades (8). The clinical significance of microPTC is still 65 
debated, and many authors consider it as non-progressive disease that has no effect on 66 
survival (1), (9-16). On clinical and histological grounds there are two different 67 
presentations of microPTC (6): a) “incidental” microPTC identified postoperatively at 68 
histological examination of thyroid specimens following thyroid surgery for benign disease, 69 
(i.e.compressive goiter) ; b) “non-incidental” microPTC, diagnosed before surgery at fine 70 
needle aspiration (FNA) of small thyroid nodules detected at neck ultrasound or at other 71 
diagnostic procedure, or for the presence of  nodal metastasis.  72 
According to some studies, “incidental” microPTC have an overall excellent prognosis 73 
and there is nearly no risk of recurrence or death (17,18), while “non incidental” 74 
microPTC show a more aggressive behaviour, eventually associated with lymph-node 75 
metastases at presentation, neck loco-regional recurrences during follow-up and/or 76 
multifocality of the tumor (6,10,16,19,20).However conflicting results are present in 77 
literature to date. Thus it is unclear whether these different presentations reflect the same 78 
disease or express two different entities with their own underlying pathophysiology 79 
(17,21-25).  80 
In the last few years it has been reported that, in patients with nodular thyroid disease, 81 
the risk of thyroid malignancy increases with increasing concentrations of serum thyroid-82 
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stimulating hormone (TSH) and, even within normal ranges, higher serum TSH levels are 83 
associated with a higher frequency and more advanced stage of thyroid cancer (26). 84 
Furthermore, it has been shown that thyroid diseases, that affect thyroid function, 85 
influencing pituitary secretion of TSH, are associated with a different risk of PTC, being 86 
the likelihood of thyroid malignancy reduced when TSH is lower, as in nodular goiter with 87 
thyroid autonomy (27) and increased when TSH is higher, as in nodular Hashimoto’s 88 
thyroiditis (28). Moreover, in patients with nodular thyroid disease, L-thyroxine (L-T4) 89 
treatment, reducing serum TSH, is associated to a significantly lower risk of developing 90 
clinically detected thyroid cancer (28). The relationship between serum TSH and 91 
microPTC is not clear, results reported in the literature being discrepant and relying  only 92 
on retrospective studies (29-35).   93 
We designed a prospective study with the aim to analyze clinical and histological 94 
presentation of “incidental” and “non incidental” microPTC and the possible role of serum 95 
TSH in each of these two entities.  96 
 97 
Subjects  and Methods  98 
Patients  99 
In this study we included consecutive patients submitted to thyroid surgery in our 100 
Institution from march 2013 to march 2014 for goiter with compressive symptoms or for 101 
nodule(s) with a cytological diagnosis suspicious or indicative of cancer. We included in 102 
the study only patients with all clinical data available (previous treatment, use of medicine 103 
affecting TSH values) and who underwent to all the diagnostic procedures described 104 
below before surgery in our Institution. 105 
The diagnostic management of patients included: thyroid ultrasound, technetium-99m-106 
pertechnetate scintiscan in patients with serum TSH lower than 0.4 mU/L, FNA of 107 
dominant cold nodules in multinodular goiter, of cold single nodules larger than 1 cm and 108 
of nodules smaller than 1 cm with suspicious findings (e.i microcalcifications, a taller-109 
than-wide shape, irregular borders and marked hypoechogenicity) at thyroid ultrasound. 110 
TSH, free thyroid hormones, serum thyroid autoantibodies (TAb) and calcitonin (CT)  111 
were measured immediately before surgery. As one aim of the study was to evaluate the 112 
role of serum TSH, patients were excluded if they were taking L-T4 or methimazole or 113 
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drugs that may affect serum TSH levels (such as corticosterois). We also excluded from 114 
the study patients with Graves’ disease, diagnosed according to the standard criteria and 115 
those with a non papillary thyroid tumors, e.g. follicular, anaplastic cancer, lymphoma and 116 
those who had high levels of CT suspicious of medullary thyroid carcinoma. All patients 117 
included in the study were submitted to total thyroidectomy. Patients included in the study 118 
were 665 (males 202, females 463, mean age 50.1 +13.8 years). All patients gave their 119 
informed consent to the study. 120 
Before surgery thyroid ultrasound was performed to determine thyroid volume and the 121 
presence of single or multiple nodules. Thyroid volume was calculated according to the 122 
formula of the ellipsoid model: (width x length x thickness x 0.52 for each lobe). A thyroid 123 
volume greater than 20 mL in males and 15 mL in females was considered as goiter (36). 124 
Patients were grouped  as follows:  125 
- patients with multiple thyroid nodules (MN = 406): in a gland of normal size (MN-no 126 
goiter n= 71) or  in  goiter (MN-goiter n= 335).  127 
-patients with a single thyroid nodule (SN = 259): in a gland of normal size (SN-no goiter, 128 
n= 122) or  in goiter (SN-goiter n= 137)  129 
The indication for surgery are summarized in table 1. In MN goiter group patients were 130 
submitted to thyroidectomy because of a large goiter with compressive symptoms 131 
(n=141) or a goiter with one or more nodules with an indeterminate (TIR3, n= 143) or 132 
suspicious or indicative of cancer (TIR4/5, n= 51) cytology. In MN-no goiter group 133 
patients had one or more nodules with an TIR3 (n= 41) or TIR4/5 (n= 29) cytology. In this 134 
group 1 patient was submitted to surgery because of a clinically suspicious thyroid nodule 135 
with a non diagnostic cytology (TIR1), increased in size during the follow up. In SN goiter 136 
group the indications for surgery were the presence of a large nodule with compressive 137 
symptoms (n=31) or a nodule with a TIR3 (n=77) or TIR4/5 (n= 29) cytology. In SN-no 138 
goiter group patients had one nodule with an TIR3 (n= 72) or TIR4/5 (n= 50) cytology 139 
 140 
Thyroid function tests  141 
Serum free T4 (FT4) and triiodothyronine (FT3) were measured by chemiluminescent 142 
immunometric assay (VITROS 3600, Siemens, Buckinghamshire, UK FT4– normal 143 
values 0.7–1.7 ng/dl; FT3–normal values 2.7-5.7 pg/ml) and expressed as ng/dl and 144 
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pg/ml respectively. Serum TSH was measured by a solid-phase, two-site 145 
chemiluminescent immunometric assay (IMMULITE 2000 Third Generation, DPC 5700 146 
Los Angeles, USA– normal values 0.4–3.4 mU/L) and expressed as mU/L. TgAb and 147 
TPOAb were measured by an immunoenzymatic assay (AIA-Pack TgAb, and TPOAb, 148 
Tosoh, Tokyo, Japan) and expressed as UI/ml. Normal values were <30 UI/ml for TgAb 149 
and <10 UI/ml for TPOAb. CT was measured by chemiluminescent immunometric assay 150 
(IMMULITE 2000, Siemens Healthcare , Llanberis, Gwynedd LL55 4EL, UK, normal 151 
values <10 pg/ml) and expressed as pg/ml.  152 
 153 
FNA and cytological diagnosis  154 
FNA was performed under echo guidance using a 23-gauge needle attached to a 10 ml 155 
syringe. The material was air-dried, stained with Papanicolaou and Giemsa. Cytological 156 
results were classified according to the criteria of the Italian Consensus for the 157 
classification and reporting of thyroid cytology (37).  158 
 159 
Histopathologic examination  160 
All specimens were accurately described (weight, shape, color and cut surface) and 161 
sampled for histology  by two independent pathologists. The entire circumference of 162 
nodules was sampled. Samples were also made for each centimeter of extra nodular 163 
parenchyma. Formalin-fixed, paraffin-embedded tissues obtained from thyroid sampling 164 
of each case were stained by hematoxylin and eosin (38). The histological diagnosis was 165 
made according to the World Health Organization guidelines 7).  166 
 167 
Statistical analysis 168 
All variables were described by statistical characteristics: categorical data were described 169 
by frequency and percentage and quantitative data by median value and interquartile 170 
range . To evaluate “the normality” of the quantitative variables distributions, the 171 
Kolmogorov-Smirnov test was applied. Two-tailed Mann-Whitney and Kruskall-Wallis 172 
tests were employed for quantitative data and Chi square test for the categorical variable.  173 
Differences were considered significant at  p<0.05. The statistical analysis was performed 174 
using the statistical software JMP 10 (SAS Institute, Cary, North Carolina, USA).  175 




Classification of patients according to thyroid ultrasound and histology  178 
According to thyroid ultrasound data, cytological diagnosis and results at histology, 179 
patients were subdivided as follows (Table 1):   180 
a) “Incidental” microPTC (Inc-microPTC, n= 92) identified postoperatively at histological 181 
examination of thyroid of patients submitted to surgery for large multinodular goiter with 182 
compressive symptoms and/or incidentally detected in the extra-nodular parenchyma of 183 
thyroid gland of patients submitted to surgery for nodules with an “indeterminate” 184 
cytological diagnosis and with a final histological diagnosis of benign nodules;  185 
b) “Non-incidental” microPTC (Non-Inc-microPTC n = 67) diagnosed before surgery as 186 
small thyroid nodule incidentally detected at thyroid ultrasound and submitted to FNAC 187 
because of the presence of “suspicious” signs at ultrasound 188 
c) PTC larger than 1 cm (macroPTC): n = 215  189 
d) Benign nodular goiter (Benign): n= 291;  190 
Inc-microPTC were significantly more frequent in multinodular glands being detected in 191 
66/406 (16.2%) patients with MN and in the extra-nodular parenchyma of 26/259 (10.0%, 192 
p = 0.02) patients with SN. On the other hand, Non-Inc microPTC were more frequent in 193 
patients with SN (33/259, 12.7%) than in MN (34/406, 8.4%, p = 0.04).  194 
Patients with Inc-microPTC were significantly older compared to Non-Inc-microPTC 195 
(mean age 53.3 +13.2 years vs 44.9 +14.8 years p = 0.0002). Age was not significantly 196 
different between Inc-microPTC and Benign (51.8 +12.7 years) and between Non-Inc-197 
microPTC and macroPTC (46.7 +14.8 years). 198 
No statistically significant differences were found between males and females in the 4 199 
groups of patients, although females were prevalent in all groups.  200 
No statistically significant differences were found in the frequency of positive serum 201 
thyroid autoantibodies in the 4 groups of patients. 202 
 203 
Tumor size and node metastasis at histology 204 
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Inc-microPTC were significantly smaller (4 mm, IR 2-7 mm) compared to Non-Inc-205 
microPTC, (9 mm, IR 7-10 mm, Mann-Whitney p <0.0001). Median size of macroPTC 206 
was 19 mm (IR 15-30 mm). 207 
We perform node neck dissection only in patients with suspicious node detected at neck 208 
ultrasound before surgery.  At histology node metastases were found in 17/67 (25.4%) 209 
patients with Non-Inc-microPTC and in 0 of 92 patients with Inc-microPTC (χ
2
 p < 0.0001). 210 
The frequency of node metastases in patients with Non-Inc-microPTC was not 211 
significantly different compared to that found in macroPTC (42/215, 19.5%, p=ns).  212 
 213 
Histological variants  214 
Out of 374 patients with micro and macroPTC, less aggressive variants were diagnosed 215 
in 285 (76.2%) patients: classic variant in 119, follicular variant in 166. More aggressive 216 
variants were found in 89/374 (23.7%): 32 tall cell, 5 solid and 52 mixed variants 217 
(including classic and follicular variants with solid areas, diffuse sclerosing, trabecular and 218 
solid variants). The frequency of the different histological variants in Inc-microPTC, Non-219 
Inc-microPTC and macroPTC is reported in Table 2. 220 
More aggressive variants were more frequent in Non-Inc-microPTC (18/67, 26.9 %) than 221 
in Inc-microPTC (11/92, 11.9%; χ
2
 p = 0.016), and not statistically significant differences 222 
were found between Non-Inc-microPTC and macroPTC (60/215, 27.9%) 223 
 224 
Multifocality  225 
Out of the 374 patients with a micro or macro PTC, a multifocal cancer was detected in 226 
192 (51.3%). 227 
 As reported in Figure 1, multifocal PTC were more frequent in Inc-microPTC (70/92, 228 
76.1%) compared to Non-Inc-microPTC (35/67, 52.2%, p=0.001) and to macroPTC  229 
(87/215, 40.5%, p<0.0001) and were not statistically different in Non-Inc-microPTC 230 
compared to macroPTC.  231 
The frequency of multifocal PTC was higher in patients with  MN (121/212, 57.1%) than in 232 
SN (71/162, 43.8%, p=0.01). No significant difference in the frequency of a multifocal 233 
PTC was observed between patients with or without goiter both in MN (91/163, 55.8% vs 234 
30/49, 61.2%) and in SN (34/72, 47.2% vs 37/90, 41.1%) groups (data not shown).  235 
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 236 
Serum TSH levels  237 
All patients had normal FT4 and FT3. In the whole study group median TSH was 0.8 238 
mU/L (IR 0.5-1.2 mU/L). As reported in Figure 2, TSH was significantly higher in Non-Inc-239 
microPTC than in Inc-microPTC (1.1 mU/L, IR 0.6-1.4 mU/L vs 0.6 mU/L, IR 0.4-1.0 mU/L, 240 
Mann Whitney p=0.0001) and in macroPTC than in Benign (0.9 mU/L, IR 0.6-1.4 mU/L vs 241 
0. 7 mU/L,  IR 0.3-1.1 mU/L, Mann Whitney p<0.0001). No significant difference was 242 
observed between Benign and Inc-microPTC and between macroPTC and Non-Inc-243 
microPTC.  244 
When patients were subdivided according to the median TSH level (0.8 mU/L), as 245 
reported in Figure 3, Inc-microPTC were significantly more frequent than Non-Inc-246 
microPTC in patients with TSH≤ 0.8 mU/L (58/92, 63.0% vs 22/67, 32.8%, p<0.0001); 247 
while Non-Inc-microPTC were significantly more frequent than Inc-microPTC (34/92, 248 
36.9% vs 45/67, 67.1%, p<0.0001) in patients with TSH >0.8 mU/L.  249 
As expected, serum TSH was lower in MN than in SN (0.6 mU/L, IR 0.3-1.1 mU/L vs 0.9 250 
mU/L, IR 0.6-1.5 mU/L, Mann Whitney p<0.0001) as consequence of development of 251 
thyroid autonomy in the first group. 252 
 253 
Discussion 254 
In the last 10–15 years, several epidemiological studies have reported an increased 255 
incidence of PTC, mainly due to tumors smaller than 1 cm in size, while the incidence of 256 
larger tumors is stable (1-4). Among newly diagnosed PTC the average prevalence of 257 
microPTC is around 39%, although different series in the same country report 258 
significantly different prevalence, pointing toward methodological or selection bias (12). 259 
The increased incidence of thyroid cancer is likely related to an increased diagnosis due 260 
to the use of ultrasound and fine needle aspiration (5) and the clinical benefit of 261 
diagnosing small thyroid cancers remains uncertain. The average rate of recurrences and 262 
deaths is 3.3% and 0.2%, respectively, cumulating different series (12). The low 263 
frequency of recurrences is not surprising in view of the evidence that several risk factors 264 
for recurrence and death (mutifocality, extrathyroidal extension, lymph node metastases, 265 
distant metastases) are dependent on the size of the primary tumor and are thus very low 266 
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in microPTC (12-16). Higher rate of multicentricity, bilaterality, invasiveness, and lymph 267 
node metastases have been reported in several series in Non-Inc-microPTC compared to 268 
Inc-microPTC (16,19,20). Thus,  to date it is unclear whether “incidental” and “non-269 
incidental” microcarcinomas reflect the same disease or two different entities.  270 
In the present study, we observed clinical and histological differences between Inc-271 
microPTC and Non-Inc-microPTC. Inc-microPTC, like benign nodular thyroid disease, 272 
were more frequent in older subjects and in multinodular goiter, while Non-Inc-microPTC, 273 
similarly to macroPTC, were more frequent in younger subjects and in single  nodules. 274 
Non-Inc-microPTC with respect to Inc-microPTC were larger and associated with a higher 275 
frequency of lymph node metastases at histological examination (25.4% vs 0%), similarly 276 
to macroPTC. The majority of microPTC presented a classic or a follicular histological 277 
variant. However more aggressive variants (such as tall cell, solid variant etc.) were more 278 
frequent in Non-Inc-microPTC (18/67, 26.9%), than in Inc-microPTC (11/92, 11.9%).  279 
It as been shown that in patients with nodular thyroid disease, the risk of papillary thyroid 280 
cancer clinically detected increases with increasing concentrations of TSH (26) and, in a 281 
mouse animal model with a thyroid-specific knock-in of oncogenic Braf, serum TSH was 282 
shown to play a key role in the development of papillary thyroid carcinoma (39). Results 283 
obtained in the present series of patients confirm our previous data (27), TSH levels 284 
being significantly higher in macroPTC with respect to benign nodular disease. Conflicting 285 
results have been reported about the relationship between serum TSH and microPTC. In 286 
a recent study  Shi et al. (29) found that TSH is not a good risk predictor for carcinomas 287 
smaller than 1 cm. Similar data were found by Gerschpacher et al. (30) and Shon et al. 288 
(31), who did not observe significant associations between serum TSH and the risk of 289 
malignancy in patients with thyroid nodules <1 cm. However, in the last study, there was 290 
a significant association between serum TSH  and malignancy in patients with thyroid 291 
nodules > 1 cm in diameter (31). On the other hand, an association between TSH and 292 
microPTC was found by Moon et al. (32), Haymart et al. (33) and Zafon et al.(34) even if 293 
in these last studies statistical significance of analysis was not reached because of the 294 
small number of enrolled patients. Published studies on microPTC are all retrospective 295 
and those analyzing the relationship between microcarcinoma and serum TSH do not 296 
distinguish between clinically overt and incidental microcarcinoma. Our  study was aimed 297 
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not only at evaluating clinical differences between incidentally discovered and clinically 298 
diagnosed microcarcinoma, but also at investigating  the possible relationship with serum 299 
TSH.  For this reason patients under treatment with L-T4 or methimazole as well as those 300 
with Graves’ disease were excluded. TSH levels were significantly lower in Inc-microPTC 301 
with respect to Non-Inc-microPTC. On the other hand, TSH levels were not statistically 302 
different between Inc-microPTC and benign nodular disease and between Non-Inc-303 
microPTC and macroPTC. In particular, in patients with serum TSH lower than the 304 
median value (0.8 mU/L), Inc-microPTC were more frequent than Non-Inc-microPTC, 305 
while in patients with TSH higher than 0.8 mU/L, Non-Inc-microPTC were more frequent.  306 
On clinical grounds the presence of lower levels of serum TSH in Inc-microPTC , more 307 
frequently associated with multinodular goiter, than Non-Inc-microPTC, usually presented 308 
as single nodule, is likely related to the development of thyroid autonomy in the first group 309 
of patients (27). It is more complicated to explain the higher frequency of multifocality at 310 
histology in Inc-microPTC with respect to Non-Inc-microPTC (76.1% vs 52.2%, p=0.001). 311 
Conflicting results are reported in literature on this matter, multifocal PTC being more 312 
commonly found in Non-Inc-microPTC in some studies (6), but not in one more recent 313 
study (35). At difference with previous papers, our study is prospective and multiple PTC 314 
foci have been accurately looked for in patients submitted to thyroidectomy and were 315 
found more frequently in MN glands than in SN. These data suggest the hypothesis that 316 
genetic and environmental factors that lead to multinodular thyroid disease may favour 317 
the occurrence of somatic mutations in follicular thyroid cells that initiate the neoplastic 318 
process of multiple little foci of papillary cancer. Support to this hypothesis is given by the 319 
observation that, in multinodular goiter, also activating mutations of TSH receptors or GS 320 
alfa, responsible for the development of functioning adenomatous nodules, are common 321 
(40).  322 
In this study we have found a statistically significant association between higher TSH 323 
levels and frequency of Non-Inc-microPTC compared to Inc-microPTC. We are aware 324 
that this observation per se does not demonstrate a pathogenetic role of TSH, but we 325 
support the hypothesis that TSH may play a role in the progression of PTC. Two different 326 
phenomena could be operating in multinodular goiter: on one site a more frequent 327 
occurrence of oncogenic mutations and, on the other, the development of  thyroid 328 
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autonomy, reducing  TSH levels, could slow down cancer progression of the multiple little 329 
foci of PTC, thus preventing the occurrence of clinically detectable carcinoma. This 330 
hypothesis can explain the relatively higher frequency of microPTC incidentally detected 331 
in older patients with multinodular goiter submitted to thyroid surgery. On the other hand 332 
in SN the probability of cancer initiation is lower, but  higher TSH levels may favour the 333 
progression of small PTC that can eventually be detected at ultrasound exam and that 334 
show, at diagnosis, histological features (such as frequency of node metastases) similar 335 
to those observed in macroPTC. Own features of the tumor, e.g. more aggressive 336 
histological variants, may also have a role together with serum TSH to explain the faster 337 
growth, the larger size, and the higher frequency of node metastasis  of clinically overt 338 
with respect  to clinically occult microPTC.  339 
In conclusion Non-Inc-microPTC and Inc-microPTC appear to be two different entities 340 
and serum TSH has probably a critical role in these two kinds of tumor.   341 
342 
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Legend of Figures 511 
Figure 1  512 
Frequency of multifocality in Inc-microPTC , Non-Inc-microPTC and macroPTC.  513 
Multifocal PTC were significantly more frequent in Inc-microPTC (black column)  (70/92, 76.1%) with 514 
respect to Non-Inc-microPTC (gray column) (35/67, 52.2%, p=0.001) and macroPTC (white column),  515 
(87/215, 40.5%, p<0.0001), and not statistically different between Non-Inc-microPTC  and macroPTC.  516 
 517 
Figure 2 518 
Box-whiskers plot of TSH levels in patients with Benign (white box), Inc-microPTC (gray box), Non-Inc-519 









 percentiles; the statistical differences 521 
between groups were evaluated using the Mann-Whitney test. TSH was significantly higher in Non-522 
Inc-microPTC than in Inc-microPTC (1.1 mU/L, IR 0.6-1.4 mU/L vs 0.6 mU/L, IR 0.4-1.0 mU/L, 523 
p=0.0001) and in macroPTC than in Benign (0.9 mU/L, IR 0.6-1.4 mU/L vs 0.7 mU/L,  IR 0.3-1.1 mU/L, 524 
p<0.0001). No significant difference between Benign and Inc-microPTC and between macroPTC and 525 
Non-Inc-microPTC. 526 
 527 
Figure 3  528 
Frequency of  Inc-microPTC and  Non-Inc-microPTC according  to TSH levels  529 
Patients were subdivided according to the median TSH value (0.8 mU/L). Inc-microPTC (black 530 
columns) were significantly more frequent than Non-Inc-microPTC (white columns) in patients with 531 
TSH≤ 0.8 mU/L (58/92, 63.0% vs 22/67, 32.8%, p <0.0001); while Non-Inc-microPTC was significantly 532 
more frequent than Inc-microPTC (34/92, 36.9% vs 45/67, 67.1%, p<0.0001) in patients with  TSH 533 
>0.8 mU/L.  534 
 535 
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Figure 2. Box-whiskers plot of TSH levels in patients with Benign (white box), Inc-microPTC (gray box), 
Non-Inc-microPTC (striped box) and macroPTC (dotted box). Results are reported as median values, 
interquartile (25th -75th percentiles) ranges  (IR)  and 10th -90th percentiles; the statistical differences 
between groups were evaluated using the Mann-Whitney test. TSH was significantly higher in Non-Inc-
microPTC than in Inc-microPTC (1.1 mU/L, IR 0.6-1.4 mU/L vs 0.6 mU/L, IR 0.4-1.0 mU/L, p=0.0001) and 
in macroPTC than in Benign (0.9 mU/L, IR 0.6-1.4 mU/L vs 0.7 mU/L,  IR 0.3-1.1 mU/L, p<0.0001). No 
significant difference between Benign and Inc-microPTC and between macroPTC and Non-Inc-microPTC.  
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Figure 3. Frequency of  Inc-microPTC and  Non-Inc-microPTC according  to TSH levels \r\nPatients were 
subdivided according to the median TSH value (0.8 mU/L). Inc-microPTC (black columns) were significantly 
more frequent than Non-Inc-microPTC (white columns) in patients with TSH≤ 0.8 mU/L (58/92, 63.0% vs 
22/67, 32.8%, p <0.0001); while Non-Inc-microPTC was significantly more frequent than Inc-microPTC 
(34/92, 36.9% vs 45/67, 67.1%, p<0.0001) in patients with  TSH >0.8 mU/L. \r\n  
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 Table 1: Indication to surgery according to clinical and cytological diagnosis and histology  
 









    
    
MN-goiter (335)     
 Compressive symptoms (141) 104 30 0 7a 
 TIR3 (143) 68 29 6 40 
  TIR4/5 (51) 0 0 8 43 
MN-no goiter (71)     
 TIR1 (1) 1b 0 0 0 
 TIR3 (41) 21 7 4 9 
  TIR4/5 (29) 0 0 16 13 
SN-goiter(137)     
 Compressive symptoms (31) 24 5 0 2 c 
 TIR3  (77) 41 8 2 26 
  TIR4/5 (29) 0 0 4d 25 
SN-no goiter (122)     
 TIR3 (72) 32 13 5 22 
 TIR4/5 (50) 0 0 22 28 
 
a
 In 3 cases the PTC nodule was not submitted to FNAB, in 2 cases false negative cytology 
b TIR 1 nodule increased in size during follow up 
c 1 false negative cytology  













(n = 92) 
Non-Inc-microPTC 
(n = 67) 
macroPTC 
(n = 215) 
Less aggressive variants (a) 
(n = 285) 
81 (88.1%)* 49 (73.1%)* 155 (72.1%) 
More aggressive variants (b) 
(n = 89) 
11 (11.9%) 18 (26.9%) 60 (27.9%) 
 
a)
 Less aggressive variants: classic and follicular 
b)
 More aggressive variants: tall cell, solid an mixed 
* p = 0.016 
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